This high EGFR mutation rate highlights the negative impact of not performing EGFR mutation testing and underscores the urgent need for broader discussion regarding the incorporation of molecular testing and targeted therapy for lung cancer in the Brazilian public and private healthcare systems. The gene discussed is EGFR; the disease is lung carcinoma.